These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 6882883)

  • 21. A nonlinear physiologic pharmacokinetic model: I. Steady-state.
    Wagner JG; Szpunar GJ; Ferry JJ
    J Pharmacokinet Biopharm; 1985 Feb; 13(1):73-92. PubMed ID: 4020623
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clearance constants in physiologically based pharmacokinetic models.
    Chen HS; Gross JF
    J Pharm Sci; 1979 Aug; 68(8):1066-7. PubMed ID: 480167
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The physiological significance of total body clearance in pharmacokinetic studies.
    Chiou WL
    J Clin Hosp Pharm; 1982 Mar; 7(1):25-30. PubMed ID: 7096575
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A new model-independent physiological approach to study hepatic drug clearance and its applications.
    Chiou WL
    Int J Clin Pharmacol Ther Toxicol; 1984 Nov; 22(11):577-90. PubMed ID: 6389376
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Application of hybrid approach based on empirical and physiological concept for predicting pharmacokinetics in humans--usefulness of exponent on prospective evaluation of predictability.
    Sayama H; Komura H; Kogayu M
    Drug Metab Dispos; 2013 Feb; 41(2):498-507. PubMed ID: 23209193
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug distribution and binding.
    Oie S
    J Clin Pharmacol; 1986; 26(8):583-6. PubMed ID: 3793947
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Protein binding and drug clearance.
    Rowland M
    Clin Pharmacokinet; 1984 Jan; 9 Suppl 1():10-7. PubMed ID: 6705422
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetic-pharmacodynamic (PK-PD) modelling in non-steady-state studies and arterio-venous drug concentration differences.
    Gumbleton M; Oie S; Verotta D
    Br J Clin Pharmacol; 1994 Nov; 38(5):389-400. PubMed ID: 7893578
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Elimination half-life of drugs: value and limitations.
    Greenblatt DJ
    Annu Rev Med; 1985; 36():421-7. PubMed ID: 3994325
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetic analysis of concentration-time data obtained following administration of drugs that are recycled in the bile.
    Colburn WA
    J Pharm Sci; 1984 Mar; 73(3):313-7. PubMed ID: 6585546
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Model-free evaluation and mean-time concept in pharmacokinetics.
    Brockmeier D
    Methods Find Exp Clin Pharmacol; 1986 Oct; 8(10):593-602. PubMed ID: 3784698
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Linear and nonlinear kinetics of drug elimination. I. Kinetics on the basis of a single capacity-limited pathway of elimination with or without simultaneous supply-limited elimination.
    van Ginneken CA; van Rossum JM; Fleuren HL
    J Pharmacokinet Biopharm; 1974 Oct; 2(5):395-415. PubMed ID: 4452943
    [No Abstract]   [Full Text] [Related]  

  • 33. General theory for rapidly establishing steady state drug concentrations using two consecutive constant rate intravenous infusions.
    Vaughan DP; Tucker GT
    Eur J Clin Pharmacol; 1975 Dec; 9(2-3):235-8. PubMed ID: 1233268
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Kinetics of drug metabolism inhibition: use of metabolite concentration-time profiles.
    Shaw PN; Houston JB
    J Pharmacokinet Biopharm; 1987 Oct; 15(5):497-510. PubMed ID: 3694494
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Physiologically based approaches towards the prediction of pharmacokinetics: in vitro-in vivo extrapolation.
    De Buck SS; Mackie CE
    Expert Opin Drug Metab Toxicol; 2007 Dec; 3(6):865-78. PubMed ID: 18028030
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of a programmable calculator to determine steady-state levels of drugs eliminated by parallel first-order and Michaelis-Menten kinetics.
    Crow JW; Levy G
    Am J Hosp Pharm; 1978 Sep; 35(9):1075-7. PubMed ID: 696752
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prediction of drug terminal half-life and terminal volume of distribution after intravenous dosing based on drug clearance, steady-state volume of distribution, and physiological parameters of the body.
    Berezhkovskiy LM
    J Pharm Sci; 2013 Feb; 102(2):761-71. PubMed ID: 23233148
    [TBL] [Abstract][Full Text] [Related]  

  • 38. On the volume of distribution at steady state and its relationship with two-compartmental models.
    Yates JW; Arundel PA
    J Pharm Sci; 2008 Jan; 97(1):111-22. PubMed ID: 17705153
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relationship of apparent systemic clearance to individual organ clearances: effect of pulmonary clearance and site of drug administration and measurement.
    Mehvar R
    Pharm Res; 1991 Mar; 8(3):306-12. PubMed ID: 2052516
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Contribution of lungs to total body clearance: linear and nonlinear effects.
    Collins JM; Dedrick RL
    J Pharm Sci; 1982 Jan; 71(1):66-70. PubMed ID: 7057383
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.